These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 28248932)

  • 1. BACE inhibitor bust in Alzheimer trial.
    Mullard A
    Nat Rev Drug Discov; 2017 Mar; 16(3):155. PubMed ID: 28248932
    [No Abstract]   [Full Text] [Related]  

  • 2. Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease.
    Egan MF; Kost J; Tariot PN; Aisen PS; Cummings JL; Vellas B; Sur C; Mukai Y; Voss T; Furtek C; Mahoney E; Harper Mozley L; Vandenberghe R; Mo Y; Michelson D
    N Engl J Med; 2018 May; 378(18):1691-1703. PubMed ID: 29719179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bad news and good news in AD, and how to reconcile them.
    Knopman DS
    Nat Rev Neurol; 2019 Feb; 15(2):61-62. PubMed ID: 30622292
    [No Abstract]   [Full Text] [Related]  

  • 4. Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer's disease.
    Egan MF; Mukai Y; Voss T; Kost J; Stone J; Furtek C; Mahoney E; Cummings JL; Tariot PN; Aisen PS; Vellas B; Lines C; Michelson D
    Alzheimers Res Ther; 2019 Aug; 11(1):68. PubMed ID: 31387606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BACE inhibition causes rapid, regional, and non-progressive volume reduction in Alzheimer's disease brain.
    Sur C; Kost J; Scott D; Adamczuk K; Fox NC; Cummings JL; Tariot PN; Aisen PS; Vellas B; Voss T; Mahoney E; Mukai Y; Kennedy ME; Lines C; Michelson D; Egan MF
    Brain; 2020 Dec; 143(12):3816-3826. PubMed ID: 33253354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, Tolerability, and Pharmacokinetics of the β-Site Amyloid Precursor Protein-Cleaving Enzyme 1 Inhibitor Verubecestat (MK-8931) in Healthy Elderly Male and Female Subjects.
    Forman M; Palcza J; Tseng J; Stone JA; Walker B; Swearingen D; Troyer MD; Dockendorf MF
    Clin Transl Sci; 2019 Sep; 12(5):545-555. PubMed ID: 31215755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. β-secretase inhibitors for Alzheimer's disease: heading in the wrong direction?
    Selkoe D
    Lancet Neurol; 2019 Jul; 18(7):624-626. PubMed ID: 31202466
    [No Abstract]   [Full Text] [Related]  

  • 8. Synthesis of Verubecestat, a BACE1 Inhibitor for the Treatment of Alzheimer's Disease.
    Thaisrivongs DA; Miller SP; Molinaro C; Chen Q; Song ZJ; Tan L; Chen L; Chen W; Lekhal A; Pulicare SK; Xu Y
    Org Lett; 2016 Nov; 18(22):5780-5783. PubMed ID: 27934506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deal watch: Lilly buys back into the BACE race for Alzheimer's disease.
    Cully M
    Nat Rev Drug Discov; 2014 Nov; 13(11):804. PubMed ID: 25323931
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacokinetics and Pharmacodynamics of the BACE1 Inhibitor Verubecestat (MK-8931) in Healthy Japanese Adults: A Randomized, Placebo-Controlled Study.
    Chris Min K; Dockendorf MF; Palcza J; Tseng J; Ma L; Stone JA; Kleijn HJ; Hodsman P; Masuo K; Tanen M; Troyer MD; van Vugt M; Forman MS
    Clin Pharmacol Ther; 2019 May; 105(5):1234-1243. PubMed ID: 30347431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lessons that can be learnt from the failure of verubecestat in Alzheimer's disease.
    Doggrell SA
    Expert Opin Pharmacother; 2019 Dec; 20(17):2095-2099. PubMed ID: 31423903
    [No Abstract]   [Full Text] [Related]  

  • 12. Synthesis and evaluation of multi-target-directed ligands with BACE-1 inhibitory and Nrf2 agonist activities as potential agents against Alzheimer's disease.
    Qu L; Ji L; Wang C; Luo H; Li S; Peng W; Yin F; Lu D; Liu X; Kong L; Wang X
    Eur J Med Chem; 2021 Jul; 219():113441. PubMed ID: 33862517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alzheimer's disease research: the future of BACE inhibitors.
    Burki T
    Lancet; 2018 Jun; 391(10139):2486. PubMed ID: 29976459
    [No Abstract]   [Full Text] [Related]  

  • 14. Alzheimer disease: BACE1 inhibitor reduces β-amyloid production in humans.
    Crunkhorn S
    Nat Rev Drug Discov; 2016 Dec; 16(1):18. PubMed ID: 28031572
    [No Abstract]   [Full Text] [Related]  

  • 15. Merck ends trial of potential Alzheimer's drug verubecestat.
    Hawkes N
    BMJ; 2017 Feb; 356():j845. PubMed ID: 28202490
    [No Abstract]   [Full Text] [Related]  

  • 16. The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer's disease patients.
    Kennedy ME; Stamford AW; Chen X; Cox K; Cumming JN; Dockendorf MF; Egan M; Ereshefsky L; Hodgson RA; Hyde LA; Jhee S; Kleijn HJ; Kuvelkar R; Li W; Mattson BA; Mei H; Palcza J; Scott JD; Tanen M; Troyer MD; Tseng JL; Stone JA; Parker EM; Forman MS
    Sci Transl Med; 2016 Nov; 8(363):363ra150. PubMed ID: 27807285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New N(4)-substituted piperazine naphthamide derivatives as BACE-1 inhibitors.
    Laras Y; Garino C; Dessolin J; Weck C; Moret V; Rolland A; Kraus JL
    J Enzyme Inhib Med Chem; 2009 Feb; 24(1):181-7. PubMed ID: 18770069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The potential of BACE inhibitors for Alzheimer's therapy.
    Potter H; Dressler D
    Nat Biotechnol; 2000 Feb; 18(2):125-6. PubMed ID: 10657070
    [No Abstract]   [Full Text] [Related]  

  • 19. [Beta-secretase inhibitor].
    Fukumoto H
    Nihon Rinsho; 2011 Dec; 69 Suppl 10 Pt 2():88-92. PubMed ID: 22755161
    [No Abstract]   [Full Text] [Related]  

  • 20. Progress toward a practical BACE-1 inhibitor.
    Hills ID; Vacca JP
    Curr Opin Drug Discov Devel; 2007 Jul; 10(4):383-91. PubMed ID: 17659479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.